Hartman Institute for Therapeutic Organ Regeneration

Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease.

TitleDeriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease.
Publication TypeJournal Article
Year of Publication2016
AuthorsFattahi F, Steinbeck JA, Kriks S, Tchieu J, Zimmer B, Kishinevsky S, Zeltner N, Mica Y, El-Nachef W, Zhao H, de Stanchina E, Gershon MD, Grikscheit TC, Chen S, Studer L
JournalNature
Volume531
Issue7592
Pagination105-9
Date Published2016 Mar 03
ISSN1476-4687
KeywordsAging, Animals, Cell Differentiation, Cell Line, Cell Lineage, Cell Movement, Cell Separation, Cell- and Tissue-Based Therapy, Chick Embryo, Colon, Disease Models, Animal, Drug Discovery, Enteric Nervous System, Female, Gastrointestinal Tract, Hirschsprung Disease, Humans, Male, Mice, Neurons, Pepstatins, Pluripotent Stem Cells, Receptor, Endothelin B, Signal Transduction
Abstract

<p>The enteric nervous system (ENS) is the largest component of the autonomic nervous system, with neuron numbers surpassing those present in the spinal cord. The ENS has been called the 'second brain' given its autonomy, remarkable neurotransmitter diversity and complex cytoarchitecture. Defects in ENS development are responsible for many human disorders including Hirschsprung disease (HSCR). HSCR is caused by the developmental failure of ENS progenitors to migrate into the gastrointestinal tract, particularly the distal colon. Human ENS development remains poorly understood owing to the lack of an easily accessible model system. Here we demonstrate the efficient derivation and isolation of ENS progenitors from human pluripotent stem (PS) cells, and their further differentiation into functional enteric neurons. ENS precursors derived in vitro are capable of targeted migration in the developing chick embryo and extensive colonization of the adult mouse colon. The in vivo engraftment and migration of human PS-cell-derived ENS precursors rescue disease-related mortality in HSCR mice (Ednrb(s-l/s-l)), although the mechanism of action remains unclear. Finally, EDNRB-null mutant ENS precursors enable modelling of HSCR-related migration defects, and the identification of pepstatin A as a candidate therapeutic target. Our study establishes the first, to our knowledge, human PS-cell-based platform for the study of human ENS development, and presents cell- and drug-based strategies for the treatment of HSCR.</p>

DOI10.1038/nature16951
Alternate JournalNature
PubMed ID26863197
PubMed Central IDPMC4846424
Grant ListDP3 DK111907 / DK / NIDDK NIH HHS / United States
R01 NS015547 / NS / NINDS NIH HHS / United States
DP2 DK098093 / DK / NIDDK NIH HHS / United States
DP2 DK098093-01 / DK / NIDDK NIH HHS / United States
NS15547 / NS / NINDS NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065